Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study Examining AGEN2034 as a Single-Agent and in Combination With AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma

NCT04607200 is registered in ClinicalTrials.gov with Agenus Inc. as lead sponsor.

NCT NCT04607200
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04607200 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study Examining AGEN2034 as a Single-Agent and in Combination With AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma
Lead sponsor
Agenus Inc.
Phase
Phase 2
Overall status
Withdrawn
Start date
February 28, 2021
Completion date
September 13, 2021
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

angiosarcoma